Categories: Research

Table of contents

Introduction
Budget significance
Reasons for past success
A decade of funding for bioinformatics
New drug discovery directions attract support
Research stalwarts draw funding for decades
New directions in translational research attract support
Expansion of the School’s...

Logic gates, similar to those that form the basis of silicon computing, can now be inserted into bacteria via genetic engineering, making it possible to manipulate bacteria to perform complicated tasks. This finding will ultimately enable cells to be programmed with more intricate functions,...

The implantable bioartificial kidney is explained in this December 6, 2010, SmartPlanet video featuring Shuvo Roy, PhD, a faculty member in the UCSF Schools of Pharmacy and Medicine.

Shuvo Roy, PhD, an engineer and research scientist, is leading a U.S. project to build the world’s first bioartificial kidney to treat end stage renal disease. The goal is to surgically implant this coffee-cup-sized device in a human patient within 5 to 7 years.

Paul Ortiz de Montellano, PhD, is the newly appointed associate dean of research in the UCSF School of Pharmacy. The associate dean of research advises the UCSF School of Pharmacy dean and leaders on research trends, issues, and opportunities and represents the School's research agenda to the...

Bo Huang, PhD, a faculty member in the Department of Pharmaceutical Chemistry, UCSF School of Pharmacy, has received one of 17 prestigious 2010 Packard Fellowships in Science and Engineering, which supports "unusually creative professors" early in their careers. Each fellow will receive an...

Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine, will receive the 2010 Therapeutic Frontiers Lecture Award from the American College of Clinical Pharmacy on October 17, 2010, in Austin, Texas at ACCP's annual meeting.

A national research project is under way to develop an surgically implantable bioartificial kidney using the latest advances in science and technology with the goal of both improving the health and lives of patients with end stage renal disease and saving health care dollars.

Michael Fischbach, PhD, is the recipient of a 2010 NIH Director’s New Innovator Award from the National Institutes of Health. Fischbach is a faculty member in the Department of Bioengineering and Therapeutic Sciences, UCSF Schools of Pharmacy and Medicine.

Kathy Giacomini, PhD, co-chair of the UCSF Department of Bioengineering and Therapeutic Sciences and an expert in the field of pharmacogenomics, is leading two research projects funded by two grants totaling $15.1 million over the next five years to expand research into how genes affect an...